Search 

The Ono Pharmaceutical Group, in keeping with our philosophy of "Dedicated to Man's Fight against Disease and Pain," has always striven to serve as an R&D-oriented international pharmaceutical company.  In this endeavor we have placed our emphasis on creating innovative medicines that meet international requirements.  In addition to its own original research and development efforts, Ono has been very activly seeking a in-licensing opportunity from companies inside and outside Japan.

Vice President, Licensing and M&A

ORCHID, in conjunction with its Indian R&D arm, USA drug discovery subsidiary, Bexel Pharmaceuticals Inc, and USA affiliate, Diakron Pharmaceuticals Inc, has new Drug Discovery programs in therapeutic areas of metabolic disorders, cardio-vascular, oncology, inflammation and anti-infectives.
It brings forth a rich pipeline of NCEs for out-licensing and recently received a milestone for an ongoing anti-infective collaboration with MERCK.
Orchid Chemicals & Pharmaceuticals Ltd. (ORCHID), an Indian Pharmaceutical company, of global standing and innovation is fuelling growth through R&D of novel small molecules and new pharmaceutical products backed by scientific, technical and manufacturing competencies and global intellectual property management.
ORCHID operates in business domains of APIs, finished dosage forms (Generics), New Drug Discovery(NCE), & Custom Research & Manufacturing Services (crams), while pursuing biotechnology based green chemistry initiatives and is assessing entry into Bio-Pharmaceuticals (bio-betters).
Orchid continues to expand its patent technologies, new chemical entities/product and services through various business propositions.

Principia Biopharma is building an integrated pharmaceutical company focused on the discovery and development of reversible covalent drugs for the treatment of autoimmune diseases and cancer.  Principia’s reversible covalent technology, which has been validated in vivo against multiple targets to date, produces molecules with superior attributes and our approach has significant advantages over standard drug development methods. 

o   It produces highly potent (low nanomolar to picomolar) compounds with increased selectivity and prolonged durability despite limited exposure.

o   Accelerates the drug development process by avoiding the need for HTS and the  provides the opportunity to evolve tool compounds into clinical candidates

o   Has a broad range of applicability across multiple target classes

Given the wealth of opportunities addressable with Principia’s technology, the company is interested in working with partners to fully exploit the technology outside of cancer and autoimmune therapeutic areas.

Fully Integrated Pharmaceutical Operations

Purdue provides partner companies with extensive expertise in discovery, clinical development, project management, regulatory affairs, manufacturing, marketing, and sales. A dedicated Alliance Management function ensures that every dimension and detail involved in our collaborations gets the attention required. Purdue has regulatory expertise and experience in gaining approval from the U.S. Food and Drug Administration (FDA). Our national U.S. sales and marketing organization has the critical mass and know-how to commercialize new products quickly and effectively.

Purdue Pharma and its independent associated companies (including the Mundipharma/Napp companies) have a presence in more than 30 countries and a staff of more than 5,000.  Each of these international companies is a leader within their respective market for key therapeutic areas.

Purdue has long-standing expertise in pain management and has transformed clinical practice to better serve the needs of patients with pain. We have conducted extensive pharma industry research into the development of analgesics that provide safe and effective pain relief to patients. We work extensively with physicians, opinion leaders, and patient advocacy groups to ensure that pain is appropriately recognized and treated.

Purdue and Shionogi & Co., Ltd., one of Japan’s largest research-based pharmaceutical companies, are collaborating on the discovery and development of new, non-opioid pain medications to treat pain. The research, which targets cellular receptors known to modulate pain responses, is being conducted jointly at Purdue’s research center in Cranbury, New Jersey, and Shionogi’s laboratories in Osaka, Japan.

Purdue has an exclusive U.S. licensing and co-promotion agreement with Labopharm Inc. of Laval, Canada for Ryzolt® (tramadol HCl extended-release tablets), an extended release formulation of tramadol.

Purdue has an exclusive license and collaboration agreement with Transcept Pharmaceuticals, Inc. to commercialize Intermezzo® (zolpidem tartrate sublingual tablet), a product for one type of insomnia.

Additionally, Purdue Pharma L.P. and its independent company, Mundipharma International Corporation Limited, entered into a global partnership with Infinity Pharmaceuticals, Inc. to advance the research, development, and commercialization of Infinity’s discoveries and early clinical programs in oncology (outside the United States) and neuropathic pain (worldwide).

Purdue’s licensing strategy seeks to identify late-stage products within the following therapeutic areas:

• Pain management – both non-opioids and opioids
• Sleep disorders
• Gastrointestinal disorders